195 related articles for article (PubMed ID: 16697272)
1. Incidence of statin hepatotoxicity in patients with hepatitis C.
Khorashadi S; Hasson NK; Cheung RC
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):902-7; quiz 806. PubMed ID: 16697272
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients.
Lobstein S; Kaiser T; Liebert U; Wojan M; Leichtle A; Mössner J; Wiegand J; Tillmann HL
Z Gastroenterol; 2008 May; 46(5):415-20. PubMed ID: 18461515
[TBL] [Abstract][Full Text] [Related]
3. Liver enzymes elevation after HAART in HIV-HCV co-infection.
Servin-Abad L; Molina E; Baracco G; Arosemena L; Regev A; Jeffers L; Schiff E
J Viral Hepat; 2005 Jul; 12(4):429-34. PubMed ID: 15985015
[TBL] [Abstract][Full Text] [Related]
4. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
Chalasani N; Aljadhey H; Kesterson J; Murray MD; Hall SD
Gastroenterology; 2004 May; 126(5):1287-92. PubMed ID: 15131789
[TBL] [Abstract][Full Text] [Related]
5. Impact of anti-hepatitis C virus (HCV) antibody on outcomes in renal transplant recipients infected with HCV.
Minz M; Sharma A; Das A; Chawla Y
Transplant Proc; 2008 Sep; 40(7):2386-8. PubMed ID: 18790242
[TBL] [Abstract][Full Text] [Related]
6. Comparative study between occult hepatitis C virus infection and chronic hepatitis C.
Pardo M; López-Alcorocho JM; Rodríguez-Iñigo E; Castillo I; Carreño V
J Viral Hepat; 2007 Jan; 14(1):36-40. PubMed ID: 17212642
[TBL] [Abstract][Full Text] [Related]
7. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
Tzefos M; Olin JL
J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes.
Chalasani N; Teal E; Hall SD
Am J Gastroenterol; 2005 Jun; 100(6):1317-21. PubMed ID: 15929763
[TBL] [Abstract][Full Text] [Related]
9. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.
Toniutto P; Fabris C; Bitetto D; Falleti E; Avellini C; Rossi E; Smirne C; Minisini R; Pirisi M
J Gastroenterol Hepatol; 2007 Nov; 22(11):1904-8. PubMed ID: 17914968
[TBL] [Abstract][Full Text] [Related]
10. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
[TBL] [Abstract][Full Text] [Related]
11. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
Snyder N; Nguyen A; Gajula L; Soloway R; Xiao SY; Lau DT; Petersen J
Clin Chim Acta; 2007 Jun; 381(2):119-23. PubMed ID: 17442291
[TBL] [Abstract][Full Text] [Related]
12. Statin therapy and serum transaminases among a cohort of HCV-infected veterans.
Henderson LM; Patel S; Giordano TP; Green L; El-Serag HB
Dig Dis Sci; 2010 Jan; 55(1):190-5. PubMed ID: 19731022
[TBL] [Abstract][Full Text] [Related]
13. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
15. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
Nichols GA; Koro CE
Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
[TBL] [Abstract][Full Text] [Related]
16. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
Pekow JR; Bhan AK; Zheng H; Chung RT
Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
[TBL] [Abstract][Full Text] [Related]
17. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
[TBL] [Abstract][Full Text] [Related]
18. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
[TBL] [Abstract][Full Text] [Related]
19. Lipid metabolism in children with chronic hepatitis C, A preliminary report.
Wisniewska-Ligier M; Wozniakowska-Gesicka T; Kups J; Sulat-Syncerek D
Hepatogastroenterology; 2006; 53(72):887-91. PubMed ID: 17153447
[TBL] [Abstract][Full Text] [Related]
20. Reduction in mortality associated with statin therapy in patients with severe sepsis.
Dobesh PP; Klepser DG; McGuire TR; Morgan CW; Olsen KM
Pharmacotherapy; 2009 Jun; 29(6):621-30. PubMed ID: 19476415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
